These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 3053241

  • 1. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.
    Wiesneth M, Hertenstein B, Bunjes D, Schmeiser T, Arnold R, Heimpel H, Heit W.
    Eur J Haematol; 1988 Sep; 41(3):243-9. PubMed ID: 3053241
    [Abstract] [Full Text] [Related]

  • 2. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM, Fijnheer R, Dekker AW, Nieuwenhuis HK, Verdonck LF.
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [Abstract] [Full Text] [Related]

  • 3. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.
    Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H.
    Blood; 1998 Dec 15; 92(12):4581-90. PubMed ID: 9845524
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Dec 15; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.
    Bone Marrow Transplant; 1999 Mar 15; 23(5):443-50. PubMed ID: 10100557
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ, Murray C, Mauch P, Anderson KC, Freedman AS, Rabinowe SN, Takvorian T, Robertson MJ, Spector N, Gonin R.
    J Clin Oncol; 1992 Jul 15; 10(7):1191-200. PubMed ID: 1607923
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G, Waldmann H.
    Bone Marrow Transplant; 1994 May 15; 13(5):597-611. PubMed ID: 8054913
    [Abstract] [Full Text] [Related]

  • 13. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients.
    Ringdén O, Pihlstedt P, Markling L, Aschan J, Båryd I, Ljungman P, Lönnqvist B, Tollemar J, Janossy G, Sundberg B.
    Bone Marrow Transplant; 1991 Mar 15; 7(3):221-6. PubMed ID: 2059758
    [Abstract] [Full Text] [Related]

  • 14. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy.
    Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F, Ashby M, Downs K.
    Aust N Z J Med; 1991 Dec 15; 21(6):850-6. PubMed ID: 1818544
    [Abstract] [Full Text] [Related]

  • 15. Effective prevention of acute GVHD following allogeneic BMT with low leukaemic relapse using methotrexate and therapeutically monitored levels of cyclosporin A.
    Hunter AE, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1992 Nov 15; 10(5):431-4. PubMed ID: 1464005
    [Abstract] [Full Text] [Related]

  • 16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec 15; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival.
    Champlin RE.
    Cancer Treat Res; 1990 Dec 15; 50():99-111. PubMed ID: 1976361
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.